• Vaccine Name: SARS-CoV CRT-N vaccine
• Target Pathogen: SARS-CoV
• Target Disease: Severe Acute Respiratory Syndrome (SARS)
• Type: DNA vaccine
• Status: Research
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: mouse
• Antigen: N protein (Kim et al., 2004)
• Immunization Route: Intravenous injection (i.v.)
• Description: A DNA vaccine encoding CRT linked to a SARS-CoV N (Kim et al., 2004)

Mouse Response

• Host Strain: C57BL/6 (Kim et al., 2004)
• Host age: 6-8 weeks (Kim et al., 2004)
• Host gender: Female (Kim et al., 2004)
• Vaccination Protocol: DNA-coated gold particles were prepared and delivered to the shaved abdominal regions of mice using a helium-driven gene gun (Bio-Rad) with a discharge pressure of 400 lb/in2. C57BL/6 mice were immunized with 2 μg of the plasmid encoding CRT/N protein. The mice received two boosters with the same dose at a 1-week interval. (Kim et al., 2004)
• Immune Response: Significantly increased neutralizing antibody titre to N protein DNA vaccine (Vaccine 5732) and significantly greater count of INF-gamma CD8_ lymphocytes within splenocytes (Kim et al., 2004)
• Challenge Protocol: Vaccinated mice challenged with DNA encoding CRT/Na nd challenged these mice with Vac-N or Vac-WT (Recombinant vaccinnia virus expressing SARS N protein or wild-type vaccinia virus, respectively) intranasally or intravenously 1 week after the last vaccination (Kim et al., 2004)
• Efficacy: significantly reduced viral titer load(Kim et al., 2004)